When should an adult with chronic obstructive pulmonary disease be vaccinated against pneumococcus, and what is the recommended sequence and timing of the pneumococcal conjugate vaccine (PCV13) and the pneumococcal polysaccharide vaccine (PPSV23)?

Pneumococcal Vaccination for Adults with COPD

Adults with COPD aged 19-64 years should receive a single dose of PCV20, PCV21, or PCV15 (followed by PPSV23 ≥1 year later), and all adults aged ≥65 years should receive pneumococcal vaccination regardless of prior vaccination status. 1

For Adults with COPD Aged 19-64 Years

COPD qualifies as a chronic lung disease, placing these patients in the immunocompetent chronic medical condition category. The 2024 ACIP guidelines provide clear vaccination pathways 1:

If Never Vaccinated or Only Received PCV7 in Childhood:

• Option A: Single dose of PCV21, PCV20, or PCV15
  • If PCV15 is chosen, follow with PPSV23 ≥1 year later
  • If PCV21 or PCV20 is chosen, the series is complete

If Previously Received PPSV23 Only:

• Give PCV21, PCV20, or PCV15 ≥1 year after the last PPSV23 dose

If Previously Received PCV13 Only:

• Give PCV21, PCV20, or PPSV23 ≥1 year after PCV13
• Review recommendations again at age 65

Important timing note: The ≥1 year interval is critical for optimal immune response in immunocompetent patients with chronic conditions 1.

For Adults with COPD Aged ≥65 Years

The approach differs based on vaccination history 1:

If Never Vaccinated or Only PCV7 in Childhood:

• Single dose of PCV21, PCV20, or PCV15
• If PCV15 is used, follow with PPSV23 ≥1 year later

If Previously Received PPSV23 Only:

• Give PCV21, PCV20, or PCV15 ≥1 year after the last PPSV23 dose

If Previously Received PCV13 Only:

• Give PCV21, PCV20, or PPSV23 ≥1 year after PCV13

If Previously Received Both PCV13 and PPSV23 at Age ≥65:

• Shared clinical decision-making for PCV21 or PCV20
• If given, administer ≥5 years after last pneumococcal vaccine

Critical Sequencing Principles

The order of vaccination matters significantly. Prior PPSV23 administration blunts the immune response to subsequent PCV vaccines 2. The FDA label for PCV20 explicitly notes that receipt of PPSV23 1-5 years prior resulted in diminished immune responses compared to those who received PCV13 first 2.

Always prioritize PCV before PPSV23 when possible 3. This sequencing maximizes immunogenicity and provides the benefit of immunologic memory that conjugate vaccines confer but polysaccharide vaccines do not 4.

Key Timing Intervals

• PCV to PPSV23: ≥1 year for immunocompetent patients with chronic conditions 1
• PPSV23 to PCV: ≥1 year minimum 1
• Between PPSV23 doses: ≥5 years 3
• For subsequent PCV after completing PCV13/PPSV23: ≥5 years 1

Common Pitfalls to Avoid

1. Don't give PPSV23 first if the patient is vaccine-naïve - this will reduce the effectiveness of subsequent PCV administration 2

2. Don't co-administer PCV and PPSV23 - they must be given sequentially with appropriate intervals 3

3. Don't forget to reassess at age 65 - patients vaccinated before age 65 need their recommendations reviewed when they reach 65 1

4. Don't give more than one PPSV23 dose after age 65 - only one dose of PPSV23 should be given at age ≥65 years, regardless of prior vaccination history 3

Practical Considerations

For COPD patients, the evidence suggests PCV13 (and by extension, the newer PCVs) provides additional benefits beyond PPSV23 alone, including formation of immunologic memory and enhanced nonspecific resistance factors 4. While the 2019 guidelines moved away from routine PCV13 for all adults ≥65 years due to herd immunity effects 3, COPD patients still have a clear indication for PCV vaccination due to their chronic lung disease.

The newer vaccines (PCV20, PCV21) offer broader serotype coverage than PCV13, making them preferred options when available 1. However, in communities with high serotype 4 disease prevalence (≥30% of invasive pneumococcal disease), PCV20 or the PCV15/PPSV23 series may be preferred over PCV21, which lacks serotype 4 coverage 1.